Affymax, Inc. Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide(TM), to Treat Anemia in Chronic Renal Failure

PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced completion of treatment and follow-up of patients with anemia due to chronic renal failure enrolled in the four-trial, Phase 3 clinical program for the investigational drug Hematide. The company expects to report topline results from all four Phase 3 trials in the second quarter of 2010. The Phase 3 clinical program enrolled approximately 2,600 chronic renal failure patients at approximately 400 clinical trial sites.